Corpus ID: 45636049

FAM chemotherapy +/- aminoglutethimide in the treatment of pancreatic carcinoma.

@article{Lipton1990FAMC,
  title={FAM chemotherapy +/- aminoglutethimide in the treatment of pancreatic carcinoma.},
  author={Allan Lipton and Harold A. Harvey and Richard J Santen and John A. Stryker and Sierra Barnes and B K Walker and Richard H. Dixon and E Givant and Mary Jo Bartholomew and C Nadjafi},
  journal={European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology},
  year={1990},
  volume={16 1},
  pages={
          12-4
        }
}
  • A. Lipton, H. Harvey, +7 authors C. Nadjafi
  • Published 1990
  • Medicine
  • European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Human pancreas contains receptors for estrogens and androgens as well as aromatase activity. FAM chemotherapy was administered to 14 patients with pancreatic cancer (seven at Stage IV). The median survival of these patients was 24.4 +/- 4.8 weeks. FAM chemotherapy plus aminoglutethimide/hydrocortisone (AG/HC) (250 mg bid AG + 20 mg bid HC) was administered to 14 patients (seven at stage IV). The median survival of this group was 17.3 +/- 2.9 weeks (P = 0.74 vs FAM alone). We conclude that… Expand
3 Citations
No standard treatment is available for advanced pancreatic cancer.
TLDR
No standard treatment is currently available for patients with advanced pancreatic cancer; future studies should screen new drugs or new combinations; and an untreated control group should be included in future comparative studies until real advantages in terms of better quality of life or improved survival are demonstrated. Expand
Other risk factors for pancreatic cancer: hormonal aspects.
TLDR
There are no data confirming a role for estrogens, androgens, CCK or their antagonists in clinical treatment of exocrine pancreatic cancer, but it is not probable that hyperstimulation with CCK alone induce pancreatic cancers. Expand
Sex steroids and their receptors in patients with tumors of the pancreas
TLDR
The content of androgen receptors positively correlated with the maximum size of the tumor, and was higher in male patients, in metastasizing tumors, in adenocarcinomas located in the body of the pancreas, and in patients without clinical and laboratory evidence of the mechanical jaundice syndrome. Expand